ArticlePloS one2013
Impact of influenza on health-related quality of life among confirmed (H1N1)2009 patients.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Critical assessment of uncertainty in economic evaluations on influenza vaccines for the elderly population in Spain.BMC infectious diseases · 2025Pooled it
- The Cost of Seasonal Influenza: A Systematic Literature Review on the Humanistic and Economic Burden of Influenza in Older (≥ 65 Years Old) Adults.Advances in therapy · 2024Pooled it
- Measuring Health Utilities in Children and Adolescents: A Systematic Review of the Literature.PloS one · 2015Pooled it
- The Impact of Influenza on Health-Related Quality of Life, Work Productivity, and Activity Impairment Among Symptomatic US Patients with Influenza.Infectious diseases and therapy · 2026Article
- Cost-effectiveness analysis of influenza vaccination with high-dose vaccine versus standard-dose quadrivalent vaccine in older adults in Spain.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Influenza Vaccination in Spain: Understanding the Impact of Suboptimal Coverage on Health, Society, and the Economy.Vaccines · 2026Review
- Article
- Cost-effectiveness of procalcitonin-guided antibiotic duration for hospitalized patients with sepsis.Critical care (London, England) · 2025Article
- Impact of influenza-like illnesses on health state utility value among Japanese children and adults.Journal of patient-reported outcomes · 2025Article
- Article
- Article
- Cost-Effectiveness of Influenza Vaccination in Healthy Children: A 10-Year Population-Based Study.Vaccines · 2024Article
- The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study.The Journal of antimicrobial chemotherapy · 2024Article
- Epidemiological and health economic implications of symptom propagation in respiratory pathogens: A mathematical modelling investigation.PLoS computational biology · 2024Article
- Long-term outcomes of survivors with influenza A H1N1 virus-induced severe pneumonia and ARDS: a single-center prospective cohort study.Frontiers in cellular and infection microbiology · 2024Article
- Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis.Health technology assessment (Winchester, England) · 2023Review
- Article
- Post-COVID-19 syndrome and quality of life impairment in severe COVID-19 Mexican patients.Frontiers in public health · 2023Article
- Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina.Vaccines · 2022Article
- Quality of Life in Post-COVID-19 Patients after Hospitalization.Healthcare (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to assess the changes in health-related quality of life (HRQL) in patients with confirmed diagnosis of influenza (H1N1)2009, and to estimate the individual and societal loss of quality-adjusted life years (QALYs) caused by the pandemic. METHODS AND
resultsLongitudinal study of patients recruited at major hospitals and primary care centers in Spain. Patients reported their HRQL (EQ-5D) during their influenza episode and seven days prior to it. A subsample was monitored to evaluate HRQL after recovery. HRQL loss was estimated as the difference between EQ-5D prior to the influenza episode and during it. Individual QALY loss (disutility multiplied by the duration of the influenza episode in days) for confirmed cases was calculated and used to estimate the societal loss in Spain (with the official estimations). A total of 432 inpatients and 563 outpatients were included, of whom 145 and 184, respectively, were followed up. Baseline mean HRQL loss was 0.58 (95% CI, 0.53-0.63) for inpatients and 0.43 (95% CI, 0.40-0.46) for outpatients. The majority of the 145 inpatients and 184 outpatients who were followed up regained initial HRQL levels, presenting a mean difference of 0.01 between the EQ-5D score prior to and after the influenza episode. Individual QALY losses for inpatients (0.031, 95% CI, 0.025-0.037) were higher than for outpatients (0.009, 95% CI, 0.007-0.011), while societal QALY losses were reversed: 94 years for inpatients and 6,778 years for outpatients. For fatal cases (an official number of 318), we estimated a QALY loss of 11,981.
conclusionsThe influenza (H1N1)2009 pandemic had a significant but temporary impact on the HRQL of the majority of confirmed in- and outpatients. The societal impact of the influenza pandemic in Spain was estimated to be higher than other acute conditions. These results provide useful data for future cost-utility analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.